Antagonist targeting microRNA-146a protects against lithium-pilocarpine-induced status epilepticus in rats by nuclear
Huilong Zhang1, Yun Qu2, Aihua Wang3
1Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China.
Abstract:
Previous studies have indicated that nuclear factor-κB (NF-κB) has an important role in the pathogenesis of epilepsy. The aim of the present study was to evaluate the expression of microRNA (miRNA)‑146a, phosphorylated (p)‑P65/P65, B‑cell lymphoma‑2(Bcl‑2)/Bcl‑2‑associated X protein (Bax) and pro‑inflammatory cytokines, such as interleukin (IL)‑6, IL‑1β and tumor necrosis factor (TNF‑α) in the brain tissue of rats with epilepsy. Sprague‑Dawley rats were used to establish the epilepsy model using the lithium‑pilocarpine method. The expression of miR‑146a, pro‑inflammatory cytokines, P‑glycoprotein (P‑gp), Bcl‑2/Bax and p‑P65/P65 were assessed by reverse transcription‑semi‑quantitative polymerase chain reaction, enzyme‑linked immunosorbent assay and western blotting, respectively. Hematoxylin and eosin staining was used to determine the pathology of epilepsy. The current findings revealed that the expression of miR‑146a was greater in the model group compared with the control group, and that the expression of miR‑146a reached a maximum at 7 days post‑treatment. The expression levels of IL‑1β, IL‑6 and TNF‑α were significantly reduced in the miR‑146a antagonist group when compared with the model group. Additionally, the expression levels of P‑gp and p‑P65/P65 were significantly reduced following the addition of the miR‑146a antagonist, whereas the expression levels of Bcl‑2/Bax significantly increased under the same conditions. Therefore, the NF‑κB pathway and miR‑146a may be potential therapeutic targets in the treatment of epilepsy.
Insights
MicroRNA-146a (miRNA-146a) and the nuclear factor-kappa B (NF-κB) pathway are implicated in epilepsy pathogenesis. Targeting these may offer new epilepsy treatments.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- Epilepsy pathogenesis involves complex molecular mechanisms.
- Nuclear factor-kappa B (NF-κB) signaling is a key pathway in epilepsy.
- MicroRNAs (miRNAs) play regulatory roles in neurological disorders.
Purpose of the Study:
- To investigate the expression of miRNA-146a, NF-κB pathway components, and inflammatory markers in an epilepsy rat model.
- To explore the therapeutic potential of targeting miRNA-146a in epilepsy.
Main Methods:
- Epilepsy model established in Sprague-Dawley rats using lithium-pilocarpine.
- Expression levels of miRNA-146a, interleukins (IL-1β, IL-6), tumor necrosis factor-alpha (TNF-α), phosphorylated P65 (p-P65)/P65, B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X protein (Bax), and P-glycoprotein (P-gp) were quantified.
- Techniques included reverse transcription-semi-quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, and western blotting.
- Histopathological changes were assessed using hematoxylin and eosin staining.
Main Results:
- MiRNA-146a expression was upregulated in epilepsy model rats, peaking at 7 days post-treatment.
- Administration of a miRNA-146a antagonist significantly reduced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α).
- The antagonist also decreased P-gp and p-P65/P65 levels, while increasing the Bcl-2/Bax ratio, indicating reduced apoptosis.
Conclusions:
- MiRNA-146a expression is elevated in epilepsy and influences key inflammatory and apoptotic pathways.
- The NF-κB pathway and miRNA-146a represent promising therapeutic targets for epilepsy treatment.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
MicroRNAs
MicroRNAs
Nuclear Power
Nuclear Fuels
Nuclear fuel consists of a fissile isotope, such as uranium-235, which must be present in sufficient quantity to provide a...
Atomic Radii and Effective Nuclear Charge
Nuclear Transmutation


